$Nexalin Technology (NXL.US)$ CFO Marilyn Elson purchased 9,500 shares of the firm's stock in a transaction that occurred on Wednesday, September 28th. The stock was purchased at an average price of $1.12 per share, with a total value of $10,640.00. Following the purchase, the chief financial officer now directly owns 835,244 shares of the company's stock, valued at $935,473.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

About Nexalin Technology

Nexalin Technology, Inc, a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders.